Journal Article

DZNE-2026-00442

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Proteomic analysis identifying proteins relevant for treatment success following experimental neonatal inflammation-sensitized hypoxia-ischemia.

Burkard, H. (First author)DZNE* ; Osredkar, D. ; Maes, E.DZNE* ; Bernis, M. E.DZNE* ; Bremer, A.-S.DZNE* ; Zweyer, M.DZNE* ; Dowling, P. ; Ohlendieck, K. ; Thoresen, M. ; Sabir, H. (Last author)DZNE*

2026
[Verlag nicht ermittelbar] London [u.a.] Nature Publishing Group

This record in other databases:    

Please use a persistent id in citations: doi:10.1038/s41390-025-04097-8

Abstract: Understanding the mechanisms of injury following neonatal hypoxic-ischemic encephalopathy (HIE) is a major goal in neonatal research. HIE can have severe effects on cognitive and motor development in newborns, including an increased risk of death. As the incidence is 10-20 times higher in low- and middle-income countries compared to developed countries, the interest in a therapy exists worldwide. Therapeutic hypothermia (HT) is the only effective treatment after HIE. However, TH is not universally effective, particularly in cases of inflammation-sensitized hypoxia-ischemia (HI); it provides limited benefit.To identify proteins that may contribute to the reduced efficacy of HT in the case of pre-HI inflammation sensitization, the proteomic profiles of animals subjected to HI and HT combined with lipopolysaccharide (LPS) were analyzed via liquid chromatography mass spectrometry (LC-MS/MS).We identified proteins that potentially support the efficacy of HT and those that prevent the success of the therapy in the neonatal rat model of inflammation-sensitized HI.This study represents a step forward in identifying proteins related to the efficacy of HT following inflammation-sensitized HI.Therapeutic hypothermia is the only available treatment for neonatal hypoxic-ischemic encephalopathy, but not effective in models of inflammation-sensitized hypoxic-ischemic brain injury. Using liquid chromatography mass spectrometry, we identified proteins possibly having an effect on the treatment success of therapeutic hypothermia following experimental inflammation-sensitized hypoxic-ischemic brain injury. This proteomic analysis reveals proteins as potential markers that could prevent or support the efficacy of therapeutic hypothermia in experimental neonatal inflammation-sensitized hypoxic-ischemic encephalopathy.

Keyword(s): Animals (MeSH) ; Hypoxia-Ischemia, Brain: therapy (MeSH) ; Hypoxia-Ischemia, Brain: metabolism (MeSH) ; Proteomics: methods (MeSH) ; Animals, Newborn (MeSH) ; Inflammation: metabolism (MeSH) ; Hypothermia, Induced (MeSH) ; Rats (MeSH) ; Disease Models, Animal (MeSH) ; Lipopolysaccharides (MeSH) ; Rats, Sprague-Dawley (MeSH) ; Chromatography, Liquid (MeSH) ; Treatment Outcome (MeSH) ; Tandem Mass Spectrometry (MeSH) ; Lipopolysaccharides

---

Contributing Institute(s):

1. Neonatal Neuroscience (AG Sabir)

Research Program(s):

1. 352 - Disease Mechanisms (POF4-352) (POF4-352)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---